# Safety and Immunity of Covid-19 aAPC Vaccine

> **NCT04299724** · PHASE1 · UNKNOWN · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 100 (estimated)

## Conditions studied

- Treat and Prevent Covid-19 Infection

## Interventions

- **BIOLOGICAL:** Pathogen-specific aAPC

## Key facts

- **NCT ID:** NCT04299724
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-15
- **Primary completion:** 2023-07-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-03-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04299724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04299724, "Safety and Immunity of Covid-19 aAPC Vaccine". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04299724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*